Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Emerald Advisers LLC

Emerald Advisers LLC increased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 58.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,242 shares of the biotechnology company's stock after purchasing an additional 4,904 shares during the quarter. Emerald Advisers LLC's holdings in Sarepta Therapeutics were worth $1,610,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Louisiana State Employees Retirement System grew its holdings in Sarepta Therapeutics by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock worth $3,222,000 after purchasing an additional 100 shares during the last quarter. Manchester Capital Management LLC grew its stake in Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after buying an additional 110 shares during the last quarter. UMB Bank n.a. increased its position in Sarepta Therapeutics by 36.0% during the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock valued at $63,000 after buying an additional 138 shares in the last quarter. CIBC Asset Management Inc increased its position in Sarepta Therapeutics by 5.1% during the 4th quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock valued at $347,000 after buying an additional 139 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in Sarepta Therapeutics by 5.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company's stock valued at $352,000 after buying an additional 145 shares during the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity

In related news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.70% of the company's stock.

Sarepta Therapeutics Price Performance

NASDAQ SRPT traded down $2.72 during trading hours on Tuesday, reaching $73.61. The company's stock had a trading volume of 1,303,489 shares, compared to its average volume of 1,223,667. The firm has a market capitalization of $7.14 billion, a price-to-earnings ratio of 58.89 and a beta of 0.79. The company's 50-day moving average is $105.44 and its two-hundred day moving average is $117.08. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a 1-year low of $73.05 and a 1-year high of $173.25.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. HC Wainwright restated a "sell" rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a report on Wednesday, March 19th. Needham & Company LLC restated a "buy" rating and set a $202.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Scotiabank lowered their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research note on Thursday, March 20th. Cantor Fitzgerald reissued an "overweight" rating and set a $163.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Finally, Piper Sandler reduced their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $167.41.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.